Similar findings were reported in previous studies in melanoma patients.14,24 The upregulation of PD-1 on CD8+ T cells under chronic and persistent antigen stimulation is well described.2 Blocking this PD-1 receptor with anti-PD-1 therapy could therefore result in activation of CD8+ T cells, and as a result enhance tumour regression. This evidence concerns the gene CD8A and neoplasm.